This clear clinical benefit provided by higher doses of Sotorasib strongly suggests that additional factors beyond the inhibition of KRAS contribute to the anti-cancer functionality of G12C inhibitors, of which activation of NRF2, induction of NISP gene expression, and the concomitant upregulation of anti-cancer immunity will play an important role. Here, KRAS is linked to cancer.